Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Socio-demographic factors associated with the progression of HIV infection and the impact of HAART in a seroconverter cohort in Madrid (1986-2009)].
Monge S, Del Romero J, Rodríguez C, de Mendoza C, de Górgolas M, Cosín J, Dronda F, Pérez-Cecilia E, Peña JM, Santos I, Rubio R, Del Amo J; Grupo de Seroconvertores de la Comunidad de Madrid. Monge S, et al. Enferm Infecc Microbiol Clin. 2012 Mar;30(3):117-23. doi: 10.1016/j.eimc.2011.07.016. Epub 2011 Oct 19. Enferm Infecc Microbiol Clin. 2012. PMID: 22014512 Spanish.
[Cardiovascular risk in human immunodeficiency virus-infected patients in Spain. CoRIS cohort, 2011].
Masiá M, Pérez-Cachafeiro S, Leyes M, López-Aldeguer J, López M, Segura F, Blanco JR, Peña A, Rodríguez F, Vera M, Del Amo J, Gutiérrez F; Grupo de estudio de riesgo cardiovascular de CoRIS. Masiá M, et al. Enferm Infecc Microbiol Clin. 2012 Nov;30(9):517-27. doi: 10.1016/j.eimc.2012.02.014. Epub 2012 Apr 30. Enferm Infecc Microbiol Clin. 2012. PMID: 22551653 Spanish.
Analysis of transmitted drug resistance in Spain in the years 2007-2010 documents a decline in mutations to the non-nucleoside drug class.
Monge S, Guillot V, Alvarez M, Peña A, Viciana P, García-Bujalance S, Pérez Elias MJ, Iribarren JA, Gutiérrez F, Itziar Casado M, Garcia F; CoRIS. Monge S, et al. Clin Microbiol Infect. 2012 Nov;18(11):E485-90. doi: 10.1111/1469-0691.12011. Epub 2012 Sep 27. Clin Microbiol Infect. 2012. PMID: 23016666 Free article.
Incidence of hepatitis C virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: increasing rates of HCV diagnosis but not of HCV seroconversions.
Sobrino-Vegas P, Monge Corella S, Serrano-Villar S, Gutiérrez F, Blanco JR, Santos I, del Romero J, Segura F, Portilla J, Guillén SM, del Amo J; CoRIS. Sobrino-Vegas P, et al. Among authors: monge corella s. PLoS One. 2014 Dec 30;9(12):e116226. doi: 10.1371/journal.pone.0116226. eCollection 2014. PLoS One. 2014. PMID: 25549224 Free PMC article.
Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain.
Mazagatos C, Mendioroz J, Rumayor MB, Gallardo García V, Álvarez Río V, Cebollada Gracia AD, Batalla Rebollo N, Barranco Boada MI, Pérez-Martínez O, Lameiras Azevedo AS, López González-Coviella N, Castrillejo D, Fernández Ibáñez A, Giménez Duran J, Ramírez Córcoles C, Ramos Marín V, Larrauri A, Monge S; SARI Sentinel Surveillance RSV Study Group. Mazagatos C, et al. Among authors: monge s. Influenza Other Respir Viruses. 2024 May;18(5):e13294. doi: 10.1111/irv.13294. Influenza Other Respir Viruses. 2024. PMID: 38716791 Free PMC article.
Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study.
Monge S, Humphreys J, Nicolay N, Braeye T, Van Evercooren I, Holm Hansen C, Emborg HD, Sacco C, Mateo-Urdiales A, Castilla J, Martínez-Baz I, de Gier B, Hahné S, Meijerink H, Kristoffersen AB, Machado A, Soares P, Nardone A, Bacci S, Kissling E, Nunes B; VEBIS‐EHR Working Group. Monge S, et al. Influenza Other Respir Viruses. 2024 Apr;18(4):e13292. doi: 10.1111/irv.13292. Influenza Other Respir Viruses. 2024. PMID: 38654485 Free PMC article.
Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023.
Fontán-Vela M, Kissling E, Nicolay N, Braeye T, Van Evercooren I, Holm Hansen C, Emborg HD, Fabiani M, Mateo-Urdiales A, AlKerwi A, Schmitz S, Castilla J, Martínez-Baz I, de Gier B, Hahné S, Meijerink H, Starrfelt J, Nunes B, Caetano C, Derrough T, Nardone A, Monge S; VEBIS-Lot4 working group; VEBIS-Lot 4 working group. Fontán-Vela M, et al. Among authors: monge s. Euro Surveill. 2024 Jan;29(1):2300670. doi: 10.2807/1560-7917.ES.2024.29.1.2300670. Euro Surveill. 2024. PMID: 38179626 Free PMC article.
Monitoring COVID-19 vaccine effectiveness against COVID-19 hospitalisation and death using electronic health registries in ≥65 years old population in six European countries, October 2021 to November 2022.
Kislaya I, Sentís A, Starrfelt J, Nunes B, Martínez-Baz I, Nielsen KF, AlKerwi A, Braeye T, Fontán-Vela M, Bacci S, Meijerink H, Castilla J, Emborg HD, Hansen CH, Schmitz S, Van Evercooren I, Valenciano M, Nardone A, Nicolay N, Monge S; VEBIS‐Lot4 working group. Kislaya I, et al. Among authors: monge s. Influenza Other Respir Viruses. 2023 Nov;17(11):e13195. doi: 10.1111/irv.13195. Influenza Other Respir Viruses. 2023. PMID: 38019704 Free PMC article.
144 results